Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV + chemotherapy (CT): Biomarker findings from ML18147.
Stefan Kubicka
Consultant or Advisory Role - Amgen; Roche
Honoraria - Amgen; Roche; Sanofi
Roger Von Moos
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche
Honoraria - Amgen; Roche
Research Funding - Roche
Expert Testimony - Amgen
Richard Greil
No relevant relationships to disclose
Javier Sastre
Honoraria - Roche
Research Funding - Roche
Pia J. Osterlund
Consultant or Advisory Role - Roche
Honoraria - Roche
Dirk Arnold
Consultant or Advisory Role - Amgen; Merck Serono; Roche
Honoraria - Amgen; Merck Serono; Roche
Research Funding - Roche
Thierry André
Consultant or Advisory Role - Amgen; Roche
Honoraria - Merck; Sanofi
Eric Van Cutsem
Research Funding - Roche
Thomas Mueller
Employment or Leadership Position - Genentech
Irmarie Reyes-Rivera
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Honoraria - Roche
Research Funding - Roche
Jaafar Bennouna
Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Roche
Honoraria - Roche